Lung Cancer Quality Performance Indicator Specifications

LCQI11 Cancer Treatment at the End-of-Life

2021

Citation: Te Aho o Te Kahu. 2021. *Lung Cancer Quality Performance Indicator Specifications: LCQI11 Cancer Treatment at the End-of-Life*. Wellington: Te Aho o Te Kahu.

Published in March 2021 by the Te Aho o Te Kahu  
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-99-002992-9 (online)  
HP 7607



This document is available at teaho.govt.nz

|  |  |
| --- | --- |
| **CCBY** | This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made. |

Contents

[Introduction 1](#_Toc65492012)

[Sources of data for indicator 1](#_Toc65492013)

[LCQI11 Cancer treatment at the end-of-life 2](#_Toc65492014)

[Measure items 2](#_Toc65492015)

[Case eligibility criteria (denominator) 3](#_Toc65492016)

[Numerator criteria 4](#_Toc65492017)

[Chemotherapy drug codes and names 4](#_Toc65492018)

# Introduction

This information is provided to make it easier for analysts to replicate our calculations. For each measure we have provided supporting information, a table and a flow diagram.

This document provides specifications for the following measure.

|  |  |  |
| --- | --- | --- |
| **Measure** | **Measure abbreviation** | **Measure type** |
| Proportion of people with lung cancer who receive systemic anti-cancer therapy within 30 days of death | SACT\_EOL | Quality improvement |

# Sources of data for indicator

* New Zealand Cancer Registry (NZCR) – a population-based register of all primary malignant diseases diagnosed in New Zealand, excluding squamous and basal cell skin cancers
* Pharmaceutical Collection (PHARMS) – a data warehouse that supports the management of pharmaceutical subsidies, and contains claim and payment information from pharmacists for subsidised dispensings
* Mortality Collection– classifies the underlying cause of death for all deaths registered in New Zealand[[1]](#footnote-1)

More information on these data sources can be found on the Ministry of Health’s website: **www.health.govt.nz**.

# LCQI11 Cancer treatment at the end-of-life

Proportion of people with lung cancer who receive systemic anti-cancer therapy within 30 days of death.

**Measure type:** quality improvement

## Measure items

| **Dataset** | **Data item** | **Description** |
| --- | --- | --- |
| NZCR | NHI | Patient identifier |
| NZCR | Cancer event ID | Cancer registration identifier |
| NZCR | Date of initial diagnosis | Date person first diagnosed with lung cancer |
| NZCR | Diagnosis year | Calendar year of first diagnosis |
| NZCR | Site | Primary organ of origin of the cancer (ICD-10-AM 8th Edition code) |
| NZCR | Morphology code | 4-digit code (ICD-O-3) for microscopic or cellular anatomy of the cancer |
| NZCR | Basis | Basis of diagnosis |
| NZCR | DHB of domicile | DHB code for domicile of patient at diagnosis |
| NZCR | DHB | DHB name based on domicile of patient at diagnosis |
| NZCR | Age at diagnosis | Age of patient at diagnosis in years |
| NZCR | Prioritised ethnicity | Ethnic group derived from patient’s ethnicity |
| NZCR | Sex | Sex of patient |
| NZCR | Deprivation quintile | NZDep2013 index of social deprivation quintile based on patient’s domicile |
| NZCR | TNM\_T | Stage at diagnosis – tumour |
| NZCR | TNM\_N | Stage at diagnosis – node |
| NZCR | TNM\_M | Stage at diagnosis – metastases |
| NZCR | Behaviour code | Neoplastic behaviour of the cancer |
| NZCR | Multiple tumour flags | Person diagnosed with more than one tumour |
| NZCR | Registration status code | Status of registration processing |
| MORT | Date of death | Date patient died |
| PHARMS | Date of dispensing | Date of dispensing of chemotherapy drugs |
| PHARMS | Chemical ID | Identifier for drug |
| PHARMS | Chemical name | Name of chemotherapy drug |
| PHARMS | Chemical ID | Identifier for drug |

## Case eligibility criteria (denominator)


|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 1 | First or only diagnosis of malignant neoplasm | Primary site | First diagnosis of lung cancer (trachea C33 or bronchus C34) |
| 2 | Exclude manually censored case | Exclusion | Registration codes not R\_C (registered complete) or R\_R (registered)  No incident cancer (exclude people with multiple tumour flags = yes)  People diagnosed following death certificate only (basis = 0)  People domiciled outside of New Zealand (DHB\_code = 999)  Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133) |
| 3 | Diagnosis date | Date of initial diagnosis | 2015–18 |
| 4 | Male or female | Sex | M or F |
| 5 | Adult patient 18 years and older at diagnosis | Age at diagnosis | 18 years and older |
| 6 | Invasive tumours | Behaviour code | 3 |
| 7 | Deceased | Date of death | Date of death is not null |

## Numerator criteria

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 8 | Number of people with lung cancer who receive systemic anti-cancer therapy within 30 days of death | SACT\_EOL | From PHARMS dataset, include patients with:   * Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320   AND   * Dispensed date is within 30 days prior to date of death |

## Chemotherapy drug codes and names

|  |  |
| --- | --- |
| **Chemical ID** | **Chemical name** |
| 3826 | Cisplatin |
| 3825 | Carboplatin |
| 2433 | Etoposide |
| 3847 | Etoposide phosphate |
| 3811 | Irinotecan hydrochloride |
| 3815 | Paclitaxel |
| 3834 | Docetaxel |
| 3842 | Gemcitabine hydrochloride |
| 3816 | Vinorelbine |
| 4088 | Pemetrexed |
| 3966 | Gefitinib |
| 3916 | Erlotinib hydrochloride |
| 1369 | Cyclophosphamide |
| 3813 | Doxorubicin |
| 2319 | Vinblastine sulphate |
| 2320 | Vincristine sulphate |



1. ICD-10-AM: causes of death were coded to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification, Eighth Edition (Source: Independent Hospital Pricing Authority). [↑](#footnote-ref-1)